Device type · DCK
C-Reactive Protein, Antigen, Antiserum, And Control
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
DCK
Immunology
Device class
Class II
FDA decisions since 2015
9
510(k), De Novo and PMA
Adverse event reports
1
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- C-Reactive Protein, Antigen, Antiserum, And Control
- Product code
- DCK
- Device class
- Class II
- Review panel
- Immunology
- Regulation
- 21 CFR 866.5270
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for DCK
Latest FDA decisions
The 8 newest of 9 since 2015.
- K-ASSAY CRP (Ver.2)510(k)
Kamiya Biomedical Company, LLC
K242170 · Decided Apr 18, 2025 · 268 days after receipt
Device type: C-Reactive Protein, Antigen, Antiserum, And Control (DCK) · Laboratory Medicine & Pathology
K201256 · Decided Nov 4, 2022 · 907 days after receipt
Device type: C-Reactive Protein, Antigen, Antiserum, And Control (DCK) · Laboratory Medicine & Pathology
- Yumizen C1200 CRP510(k)
K192028 · Decided Jun 25, 2020 · 335 days after receipt
Device type: C-Reactive Protein, Antigen, Antiserum, And Control (DCK) · Laboratory Medicine & Pathology
6 more FDA decisions with a free account
Reports received
1
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
1
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 1 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- High Test Results1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions1
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- VITROS Chemistry Products CRP Slides. One sales unit contains 5 cartridges, of 18 slides per cartridge, for a total of 90 slides.Open, Classified
Ortho-Clinical Diagnostics, Inc.
Z-1876-2025 · Started Apr 14, 2025 · Posted by FDA May 29, 2025
Reason given: Product was incorrectly assigned GEN 88 instead of GEN 83 on product carton, foil wrapper, and cartridge (cart) label.
Cause as FDA categorized it: Process control
Ortho-Clinical Diagnostics, Inc.
Z-0535-2025 · Started Oct 11, 2024 · Posted by FDA Nov 25, 2024
Reason given: May Generate Negatively Biased Results When Testing Samples with High Concentrations of CRP, showing less than upper AMI of 90 mg/L (in the 70-90 mg/L range) while the samples having higher than 90 mg/L. User no way to know if the sample has to be diluted to measure again.
Cause as FDA categorized it: Under Investigation by firm
- CRP Immunoturbidimetric reagent. Intended for the quantitative in vitro determination of CRP concentration in serum Catalogue number: CP3826Open, Classified
Z-1286-2023 · Started Feb 1, 2023 · Posted by FDA Sep 30, 2024
Reason given: The Antibody (R2 reagent) is showing a positive bias compared to previous batches on patient samples. Quality Controls do not show the same bias and will be within range
Cause as FDA categorized it: Under Investigation by firm
14 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.